Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 1:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control (Placebo) Clear all
Terminated Phase 2 Interventional

BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

NCT00458861
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BG9924, Placebo Comparator
Biological · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 23, 2026, 1:01 AM EDT
Terminated Phase 2 Interventional

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

NCT01425970
View directory record Official record
Conditions
Hepatitis C
Interventions
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anaheim, California • La Jolla, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 23, 2026, 1:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Ashwagandha Root Extract on Stress, Anxiety, and Sleep Quality in Adults Experiencing Minority Stress

NCT07441070
View directory record Official record
Conditions
Minority Stress, Psychological Stress, Anxiety
Interventions
Ashwagandha Root Extract, Placebo Capsule
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

NCT04921969
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
64
States / cities
Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 23, 2026, 1:01 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

NCT06867094
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
SAR441566, SAR441566 matching Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
19
States / cities
Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Phase 1 Interventional

VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

NCT03562494
View directory record Official record
Conditions
Parkinson's Disease
Interventions
VY-AADC02, Sham (Placebo) Surgery
Biological · Other
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Irvine, California • Sacramento, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder

NCT02069366
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 23, 2026, 1:01 AM EDT
Terminated Phase 2 Interventional Results available

Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

NCT01783522
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Multiple Myeloma, Peripheral Neuropathy
Interventions
glutamine, quality-of-life assessment, placebo
Drug · Other
Lead sponsor
Beth Faiman
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Sep 23, 2026, 1:01 AM EDT
Terminated Phase 1 Interventional

A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine

NCT06628622
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
BI 1356225, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Los Alamitos, California • Los Angeles, California • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

NCT06500429
View directory record Official record
Conditions
Overweight and Obesity, Healthy
Interventions
NG101, Placebo, Semaglutide Injectable Product
Drug
Lead sponsor
Neurogastrx, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 23, 2026, 1:01 AM EDT
Terminated Phase 2 Interventional

DNS-7801 vs. Placebo in Parkinson's Disease

NCT03306329
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DNS-7801 (low-dose), DNS-7801 (high dose), Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
30 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
Long Beach, California • Pasadena, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

NCT03667053
View directory record Official record
Conditions
Hypoglycemia
Interventions
dasiglucagon, placebo, GlucaGen HypoKit
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
6 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Escondido, California • New Haven, Connecticut • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo, Fluticasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Sep 23, 2026, 1:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Use of Nicotine Pouches Among Daily Smokers

NCT06043362
View directory record Official record
Conditions
Tobacco Dependence
Interventions
0 mg nicotine pouch, 3 mg nicotine pouch, 6 mg nicotine pouch, Smooth nicotine pouch, Wintergreen nicotine pouch
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 70 Years
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Hershey, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 23, 2026, 1:01 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Eplerenone and IOP in Healthy Adults

NCT07795762
View directory record Official record
Conditions
Intraocular Pressure (IOP), Healthy Adult
Interventions
Eplerenone, Microcrystalline Cellulose NF (placebo)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees

NCT01925261
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
TPX-100 50mg, TPX-100 100mg, TPX-100 200mg, TPX-100 20mg, Placebo
Drug
Lead sponsor
OrthoTrophix, Inc
Industry
Eligibility
25 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Phase 3 Interventional

Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer

NCT00362986
View directory record Official record
Conditions
Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sunscreen, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
208
States / cities
Jacksonville, Florida • Aurora, Illinois • Bloomington, Illinois + 130 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults

NCT05118386
View directory record Official record
Conditions
RSV Infection
Interventions
RSM01, Placebo
Drug · Other
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
18 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

NCT03443869
View directory record Official record
Conditions
CMV Disease
Interventions
Letermovir, Valganciclovir, Acyclovir (ACV), Placebo to ACV, Placebo to LET, Placebo to VGCV
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00705783
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole depot, Placebo depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
43
States / cities
Chandler, Arizona • Anaheim, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Not applicable Interventional

Intra Hemodialytic Oral Protein and Exercise (IHOPE)

NCT01234441
View directory record Official record
Conditions
Kidney Diseases
Interventions
Control, Protein, Protein + Exercise
Dietary Supplement · Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
30 Years to 80 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Phase 1 Interventional

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

NCT04538794
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
CDX-0159, Normal Saline
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Gilbert, Arizona • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 23, 2026, 1:01 AM EDT
Withdrawn Phase 3 Interventional

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

NCT02174094
View directory record Official record
Conditions
Dravet Syndrome
Interventions
Clobazam, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
1 Year to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
8
States / cities
Los Angeles, California • Orlando, Florida • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 23, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

NCT00940602
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Deferasirox, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
11
States / cities
Anaheim, California • Greenwood Village, Colorado • Shreveport, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 23, 2026, 1:01 AM EDT